Patent application number | Description | Published |
20090148925 | Single chain class I major histocompatibility complexes - A recombinant polypeptide and nucleic acid constructs capable of expressing the recombinant polypeptide are provided. The recombinant polypeptide comprises a chimeric polypeptide including an antigenic peptide being capable of binding a human MHC class I, a functional human β-2 microglobulin and a functional human MHC class I heavy chain. | 06-11-2009 |
20090258393 | SINGLE CHAIN CLASS I MAJOR HISTOCOMPATIBILITY COMPLEXES, CONSTRUCTS ENCODING SAME AND METHODS OF GENERATING SAME - Provided are methods of generating a functional mammalian single chain MHC class I complex in prokaryotic expression systems and a host cell transformed with expression construct(s) capable of expressing a functional human single chain MHC class I complex capable of presenting specific antigenic peptides restricted to specific CTL clones. | 10-15-2009 |
20090306578 | Artificial receptors - Antibodies are provided. For as example, an antibody capable of binding an artificial receptor which comprises a hydroquinone monolayer and is incapable of binding the artificial receptor when comprising a benzoquinone monolayer. Also provided are methods and systems using same for control delivery of a molecule-of-interest into a tissue. | 12-10-2009 |
20100062001 | Antibodies for selective apoptosis of cells - A recombinant isolated antibody and a pharmaceutical composition containing same, capable of specifically recognizing an MHC-peptide complex with an affinity in a nanomolar range and of inducing apoptosis in cancer or pathogen infected cells is provided. Also provided are method for treating and diagnosing cancer or pathogen infection in a subject using the recombinant isolated antibody of the present invention. | 03-11-2010 |
20100080805 | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof - A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed. | 04-01-2010 |
20100111957 | METHODS OF DIAGNOSING AND TREATING CYTOMEGALOVIRUS DISEASES - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies. | 05-06-2010 |
20100158927 | ANTIBODIES, METHODS AND KITS FOR DIAGNOSING AND TREATING MELANOMA - A method of diagnosing melanoma and antibodies capable of same are disclosed. The method comprises contacting a cell of the subject with an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a tyrosinase peptide, wherein the antibody does not bind the MHC-I in the absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC, under conditions which allow immunocomplex formation, wherein a presence of the immunocomplex or level thereof is indicative of the melanoma. Methods for treating melanoma and antibodies capable of same are also disclosed. Pharmaceutical compositions comprising antibodies are also disclosed. | 06-24-2010 |
20100228007 | MHC-PEPTIDE COMPLEX BINDING LIGANDS - Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands. | 09-09-2010 |
20100310534 | T CELL SUBPOPULATIONS CAPABLE OF TREATING CANCER - A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8 | 12-09-2010 |
20110020357 | ANTI HUMAN IMMUNODEFICIENCY ANTIBODIES AND USES THEREOF - Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with a human immunodeficiency virus (HIV) peptide, wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing HIV infection and treating AIDS. | 01-27-2011 |
20110033473 | ANTI INFLUENZA ANTIBODIES AND USES THEREOF - Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with an influenza peptide wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing and treating influenza. | 02-10-2011 |
20110150874 | FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME - This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human β-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof. | 06-23-2011 |
20110293616 | Antigen-presenting complex-binding compositions and uses thereof - A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed. | 12-01-2011 |
20110318369 | ANTIBODY HAVING A T-CELL RECEPTOR-LIKE SPECIFICITY, YET HIGHER AFFINITY, AND THE USE OF SAME IN THE DETECTION AND TREATMENT OF CANCER, VIRAL INFECTION AND AUTOIMMUNE DISEASE - An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen and optionally further comprises an identifiable or therapeutic moiety conjugated to the antibody. | 12-29-2011 |
20120003249 | IMMUNO-MOLECULES CONTAINING VIRAL PROTEINS, COMPOSITIONS THEREOF AND METHODS OF USING - An immuno-molecule which comprises a soluble human MHC class I effector domain; and an antibody targeting domain which is linked to the soluble human MHC class I effector domain, methods of making same and uses thereof. | 01-05-2012 |
20130101594 | ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies. | 04-25-2013 |
20130115218 | ISOLATED HIGH AFFINITY ENTITIES WITH T-CELL RECEPTOR LIKE SPECIFICITY TOWARDS NATIVE COMPLEXES OF MHC CLASS II AND GLUTAMIC ACID DECARBOXYLASE (GAD) AUTOANTIGENIC PEPTIDES - Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated GAD autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated GAD autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated GAD autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated GAD autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes. | 05-09-2013 |
20130189284 | ANTIBODIES WITH T-CELL RECEPTOR LIKE SPECIFICITY TOWARDS NATIVE COMPLEXES OF MHC CLASS II AND DIABETES-ASSOCIATED AUTOANTIGENIC PEPTIDES - Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes. | 07-25-2013 |
20140170168 | ANTIBODIES WHICH BIND SOLUBLE T-CELL RECEPTOR LIGANDS - Provided are isolated high affinity entities which comprise an antigen binding domain which specifically binds a soluble T-cell receptor ligand comprising a two-domain beta1-alpha1 of a major histocompatibility complex (MHC) class II, wherein said antigen binding domain does not bind a complex comprising a four-domain alpha1-beta1/alpha2-beta2 MHC class II. Also provided are methods and kits using same for detecting and sequestering soluble two-domain T cell receptor ligands in a sample. | 06-19-2014 |
20140363440 | ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies. | 12-11-2014 |